|Videos|December 13, 2022
Risk Stratification and Frontline Treatments in Patients with Advanced Renal Cell Carcinoma
Author(s)Eric Jonasch, MD
Dr Eric Jonasch factors that contribute to a patient’s risk status, and how a patient’s risk status impacts front-line treatment choices for patients with advanced RCC.
Advertisement
Episodes in this series
Advertisement
Related to this article
LITESPARK-012 data at ESMO 2026 show that adding belzutifan or quavonlimab to pembrolizumab/lenvatinib did not improve survival for advanced kidney cancer.
Updated ARC-20 data show casdatifan delivers durable responses and strong survival in clear cell renal cell carcinoma, alone and in key first-line combinations.
Advertisement
Advertisement
Trending on Targeted Onc
1
ESMO 2026: ADCs and New Combinations Advance Lung Cancer Care
2
Novel ADCs Show Responses in Ovarian and Cervical Cancer at ESMO 2026
3
ESMO 2026: New Data Advance Prostate, Kidney, and Bladder Cancer Care
4
340B Contract Pharmacy Case Rekindles Scrutiny Over Program Intent
5